iTeos Therapeutics
ITOS
ITOS was delisted on the 28th of August, 2025.
144 hedge funds and large institutions have $389M invested in iTeos Therapeutics in 2023 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 58 increasing their positions, 48 reducing their positions, and 15 closing their positions.
131% more call options, than puts
Call options by funds: $7.51M | Put options by funds: $3.25M
21% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 48
1.96% more ownership
Funds ownership: 97.22% → 99.18% (+2%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 15
1% less funds holding
Funds holding: 146 → 144 (-2)
16% less capital invested
Capital invested by funds: $460M → $389M (-$71.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$9.25M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$6.4M |
| 3 |
BlackRock
New York
|
+$4.74M |
| 4 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
+$4.59M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
+$4.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$7.05M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
-$6.32M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
-$4.48M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$3.1M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.4M |
ITOS Hedge Fund Activity: Q3 2023 in Review
144 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in iTeos Therapeutics (ITOS) for Q3 2023, worth a combined $389M — down 16% from $460M a quarter earlier.
Fund positioning in ITOS was balanced in Q3 2023: 15 funds opened new positions, 15 closed out, 58 added to existing stakes and 48 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $9.25M. The largest seller was BVF Inc, cutting an estimated $7.05M.
- 144 institutional investors held iTeos Therapeutics (ITOS) as of Q3 2023, down from 146 in Q2 2023.
- Funds reported $389M of iTeos Therapeutics stock for Q3 2023, down 16% quarter-over-quarter.
- 15 funds opened new iTeos Therapeutics positions in Q3 2023 and 15 closed out, a net change of 0 holders.
- The largest iTeos Therapeutics buyer in Q3 2023 was Deerfield Management, an estimated $9.25M added.
- The largest iTeos Therapeutics seller in Q3 2023 was BVF Inc, an estimated $7.05M sold.
Based on aggregated 13F filings for Q3 2023.